quinazolines has been researched along with gsk2141795 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bayani, N; Billig, J; Collisson, EA; Cooper, B; Esch, A; Feiler, H; Gray, JW; Griffith, OL; Heiser, M; Hung, JL; Itani, S; Jakkula, L; Korkola, JE; Kuo, WL; Lu, Y; Mills, GB; Mukherjee, S; Oates, C; Spellman, PT; Thompson, W; Tomlin, C; Wang, NJ; Ziyad, S | 1 |
1 other study(ies) available for quinazolines and gsk2141795
Article | Year |
---|---|
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diamines; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Mutation; Oxadiazoles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction | 2015 |